Cardiovascular Ischemic Heart Disease Group E

Slides:



Advertisements
Similar presentations
Bios Life Complete Eradicating Americas Top Killer © Unicity, Inc., 2006.
Advertisements

Maenne Okunola Pharm D. Candidate: University of Georgia June 2012 Preceptor: Dr. Ali Rahimi.
Ischaemic Heart Disease
The Burden of Obesity in North Carolina Healthy People 2010 Objectives, U.S.
Linking 25% of UK FPs pay to quality of care: a major experiment in quality improvement Martin Roland Director National Primary Care Research and Development.
The identification of risk factors and diagnosis of coronary heart disease in men and women prior to their first acute myocardial infarction. Barbara P.
Proteinuria and Haematuria – an update Alex Heaton
CKD ML/LH What are people hoping to cover from the session today?
Leadership. Knowledge. Community. Antiplatelet Therapy for the Primary Prevention of Vascular Events Working Group: Alan D. Bell, MD, CCFP and James D.
Summary Prepared by Melvyn Rubenfire, MD
Niacin Use in Patients with Low HDL-Cholesterol Receiving Intensive Statin Therapy William E. Boden, MD, FACC, FAHA Jeffrey Probstfield, MD, FACC, FAHA.
Addressing Obesity and Exercise in Primary Care GSP 4 th Year Elective 2010.
Diet Preventing Diseases: Lessons from HSFSA Shân Biesman-Simons RD(SA)
What is cholesterol? Cholesterol is a waxy, fatlike substance that is naturally present in cell walls or membranes everywhere in the body. Your body uses.
Plant Sterols – a product case study
Jeannie Hayhurst Cardiovascular Specialist Nurse.
Nurse Led Clinics Opportunity for nurses to make a difference Wilma Scholte op Reimer, RN, PhD Amsterdam School of Health Professions Academic Medical.
Blood Pressure and Diabetes Colin M. Dayan University of Bristol/UBHT.
Am I At Risk? If you have any of these risk factors, you are at risk for heart disease. Controllable Risk Factors Uncontrollable Risk Factors High Cholesterol.
Mrs. Rivas Pg 75 # 3-25 ALL. Mrs. Rivas Pg 75 # 3-25 ALL.
Hypertension & Cardiovascular Risk Factors Final Year Cardiology Teaching
SHAHKUR SHABIR GP REGISTRAR DR ELLA RUSSELL -GP TRAINER SUNNYBANK MEDICAL CENTRE OCT 2011.
Algorithm Dr. Patrice Junod Clinique médicale l’Actuel This activity is supported by an educational grant from:
©PPRNet 2014 Impact of Patient Engagement on Treatment Decisions and Patient-Centered Outcomes in the Implementation of New Guidelines for the Treatment.
The Macstrak Project ER Case Studies The following is a series of case studies to review different patient types and how they are captured on the form.
S TANDARD N ORMAL C ALCULATIONS Section 2.2. N ORMAL D ISTRIBUTIONS Can be compared if we measure in units of size σ about the mean µ as center. Changing.
Lipid Management in 2015: Risk & Controversies
EXERCISE IDEAS FOR BUSY PEOPLE By Kris Fox, PhD, ATC, CSCS*D.
Ischaemic Heart Disease- Implications of Gender Dr Kaye Birks School of Rural Health Monash University Australia Gender Competency Training for Medical.
© 2006, François Brouard Case Real Group François Brouard, DBA, CA January 6, 2006.
Impact of Recent Guidelines Recommendations on Hypertension Management Fleetwood Loustalot, Ph.D., F.N.P. Lead, Epidemiology, Surveillance and Health Services.
5S CLÍNICA MÉDICA (MH) 306 A. 5S CLÍNICA MÉDICA (MH) 306 B.
Sudden numbness or weakness of the face, arm or leg, especially on one side of the body Sudden confusion, trouble speaking or understanding Sudden trouble.
© Continuing Medical Implementation ® …...bridging the care gap Cardiovascular Disease in the Elderly Patient A Global Perspective.
Healthy Living Factors in Preventing Serious Disease ( Diabetes, Cancer Heart Attack, Stroke)
Women's Health Study: Low-Dose Aspirin in Primary Prevention Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Dr.
Adrian Edwards Shared Decision Making in Cardiology: Training Workshop.
Chapter 16 Circulation. Section 3 Cardiovascular Diseases – Diseases of the cardiovascular system include atherosclerosis and hypertension – Atherosclerosis.
Coronary Artery Disease  Coronary artery disease is one of the most common and serious effects of aging. Fatty deposits build up in blood vessel walls.
Stang, A; Stang, M An Inter-State Comparison of Cardiovascular Risk Factors in Germany: Towards an Explanation of High Ischemic Heart Disease Mortality.
The Surgeon Generals Report indicates that more than half of American youth ages 12 to 21 are not vigorously active on a regular basis. Participation.
SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.
LIPID: Long-term Intervention with Pravastatin in Ischemic Disease Purpose To determine whether pravastatin will reduce coronary mortality and morbidity.
Standard Normal Distribution.  P ,33,34,35.
CARDIOVASCULAR DISEASES Heart Attack Definition- is the death of part of the heart muscle caused by lack of blood flow to the heart. A heart attack can.
Risk Factors for Coronary Heart Disease.. Did you know that…. In the UK, someone has a heart attack every 2 minutes, that’s 260,000 people per year. In.
Cardiovascular Outcome Strategy Implications for Primary Care Westcliffe Medical Practice Shipley Westcliffe Cardiology Service Dr Matthew Fay Westcliffe.
WEEK 1 You have 10 seconds to name…
Coronary Heart Disease Prevention Hutton Rudby Surgery July
Smoking Research has shown that smoking increases heart rate, blood pressure, tightens major arteries, and can create irregularities in the timing of.
CVD MEETING 7/9/01: main topics CV CLINIC WITH SCREEN SHOTS AND AUDIT MANAGEMENT PROTOCOL WITH DRUGS AND RISK CALCULATION CHARTS ASPIRIN AUDIT.
Atherosclerosis By Aravind Kalathil, Sam Eiswirth, and Brooke Turner.
Presented by Slyter Nutrition Consulting Services.
Diabetes Care Planning Interim Results
Physical Health and People with a Severe Mental Illness
HEART AND CARDIOVASCULAR SYSTEM DISEASES
CASE HISTORY ISCHEMIC HEART DISEASE
(B.P :51) ( B:P52 ).
TNT: Baseline and final LDL cholesterol levels
SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.
B.M. Biccard, R.N. Rodseth  British Journal of Anaesthesia 
عوامل اجتماعی موثر بر سلامت
Generalized Cost-Effectiveness Analysis of Pharmaceutical Interventions for Primary Prevention of Cardiovascular Disease in Thailand  Panrasri Khonputsa,
Train-the-Trainer Cases
Uninsured during the year
Uninsured and Underinsured Adults with Chronic Conditions Are More Likely to Visit the ER for Their Conditions Percent of adults ages 19–64 with at least.
Receiver operating curves (ROC) of simple age and gender adjusted risk factor models for predicting 10-year risk of cardiovascular disease comparing the.
Train-the-Trainer Cases
Appropriate Use Criteria for coronary revascularization in patients with stable ischemic heart disease: What the surgeon needs to know  Harold L. Lazar,
HR for mortality in ischemic heart disease.
Presentation transcript:

Cardiovascular Ischemic Heart Disease Group E

Presentation Scenario Mrs TZ, aged 60 years, takes the following medications on a regular basis.  Moduretic 50/5 1 M (commenced 3 weeks ago) Norvasc 10mg 1 D Plavix 75mg 1 D Recent clinical chemistry data: Recent BP readings: Total Cholesterol 7.6mmol/L (<5.5) 180/95, 185/90, 185/95 Triglycerides 3.3mmol/L (<2.0) HDL 0.7mmol/L (0.9-2.0)   Estimate her LDL. Some medications are known to have an adverse effect on lipid levels. Which medications in Mrs TZ regimen effect lipid levels? Is the effect of thiazide diuretics on the lipid profile of clinical significance? When do thiazide diuretics impact on lipid levels occur with respect to drug therapy and is it a sustained effect? What is the mechanism of thiazide induced effect on lipid levels? Disorders in lipoprotein metabolism (dyslipidemia) can result in premature atherosclerosis or pancreatitis. The accurate classification of dyslipidemias is critical to the appropriate treatment of dyslipidemia. Define what specific tests are performed to classify dislipidemias and the specific results expected for each Fredrickson class of dislipidemia.

LDL-C Estimations Laboratory measurements of total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C) and fasting triglyceride (TG) allow low-density lipoprotein cholesterol (LDL-C) to be calculated. LDL-C = TC – TG/2.2 – HDL-C LDL-C = 7.6 – 3.3/2.2 – 0.7 LDL-C = 5.4mmol/L (<3.5mmol/L)

Medication Related Lipid Changes Plavix/clopidogrel 75mg d - Alterations to the lipid profile not documented Norvasc/amlodipine 10mg d - Exerts an artheroprotective effect by reducing LDL-C accumulation and aggregation Moduretic/hydrochlorothiazide 50mg & amiloride 5mg - Alterations to lipid profile are a well established and common ADR of thiazide diuretics. - Alterations to the lipid profile not documented for amiloride a K-sparing diuretic.

HCTZ Induced Lipid Changes There are differences in the nature and extent of lipid-level changes reported A paper that surveyed the literature (31 studies) found 1) TC increases of 3.8% (ldTZ) and 6.3% (hdTZ) 2) TG increases of 10.8% (ldTZ) and 19.5% (hdTZ) A separate study found no statistically significant differences in cholesterol levels from baseline to 36 months during ldTZ therapy when adjusted for age, weight, baseline dietary percentage fat and saturated fat.

HCTZ Induced Lipid Changed Cont’ The magnitude of the reported change in lipid levels differs significantly and is dependent on - 1) study population variables (age, gender, disease state) 2) the nature of the study (duration, placebo-controlled) 3) the dose of drug used (ldTZ vs hdTZ)

Clinical Significance of Thiazide Induced Lipid Changes To be clinically significant a relationship between the measured change and a clinical outcome (ie mortality/morbidity) should be shown Establishing clinical significance is difficult - the artherosclerotic process is complex and dynamic - the follow-up period must be long enough to detect an eventual impact on morbidity There is no consensus on the clinical significance of thiazide induced lipid changes

Clinical Significance of Thiazide Induced Lipid Changes Cont’ Study #1 (middle-aged, treated hypertensive men) - High entry-level TC and TG levels +ive predictors of CHD - TZ induced TC elevation independent +ive predictor of CHD - TZ induced TG elevation not a independent +ive predictor of CHD Study #2 (middle-aged, normotensive, healthy men and women) No statistically significant TC, LDL-C, TG, HDL-C increases No increase in adverse cardiovascular events Potential sex differences

Clinical Significance of Thiazide Induced Lipid Changes Cont’ Early studies showed lower than expected reductions in CAD for TZ treated patients and commentators hypothesized that TZ induced metabolic changes might be the cause. More recent studies have demonstrated that for hypertensive patients, any -ive effect of ldTZs on the lipid profile are more than balanced by the overall decrease in the risk of stroke, CVD and death. Data from new studies that are comparing ‘metabolically neutral’ anti-hypertensive agents with traditional 1st line agents will provide us with more information.

Thiazide Induced Lipid Changes are Dose-dependent Meta-analysis have shown that the effects of thiazides are related to dose. Older studies that used high doses (>50mg/d) consistently found increased cholesterol levels. More recent studies have had varying results. Some have found that even low doses of thiazides (12.5-25mg/d) can increase serum cholesterol levels, but others have not found any change in cholesterol levels with low doses. 

When do Thiazide Induced Lipid Changes Occur and are they Sustained? Plasma cholesterol levels rises during the first 3 months of treatment but at 12 months the cholesterol level falls to below baseline. The lowering of HDL-C is an unfavourable alteration, findings indicates that the lipid-lipoprotein disturbance of diuretic therapy does indeed persist but may manifest itself differently in long term study.

Thiazide Induced Lipid Changes In summary, elevation of serum cholesterol concentrations with thiazide appears to be a short term phenomenon, since most studies indicate the elevation reverts to baseline during long term treatment.

The Mechanism Of Thiazide Induced Lipid Changes Thiazide diuretics have been shown to increase total cholesterol and serum LDL levels. In clinical studies no effects on VLDL or HDL were reported. The cause of metabolic lipid changes in uncertain.

Mechanism Cont’ One explanation is the stimulation of catecholamine release in response to the diuretic induced volume depletion. Catecholamines stimulate endogenous hepatic cholesterol synthesis. 

Mechanism Cont’ Another possibility is that it is not the diuretic itself that is causing the metabolic changes but the resultant hypokalemia. It has been proposed that hypokalemia causes a diminished pancreatic insulin release and insulin resistance with impaired muscle uptake of glucose in response to insulin. This reduction in insulin sensitivity causes glucose intolerance and may result in increased hepatic reduction of cholesterol.   Studies have shown that estrogens are likely to be an effective protective mechanism as premenopausal women experienced no lipid changes as opposed to postmenopausal.

Mechanism Cont’ Studies have indicated that changes in lipid levels are primarily associated with higher dosages of thiazide diuretics. Back in the 1960’s doses of hydrochlorothiazide were as high as 200mg daily. Nowadays it is understood doses above 25mg daily do not further increase hypertension control due to the flat dose response curve.  

Mechanism Cont’ It is important to monitor and consider any changes to the lipid profile as each % point reduction in total cholesterol may reduce risk of cardiovascular mortality by 2%.

Classification of Dyslipidemia Phenotype Average of overnight serum Lipoprotein(s) Elevated Blood Cholesterol Levels Blood Triglyceride Levels Atherogenicity I Creamy top layer Chylomicrons normal to ↑ ↑ ↑ ↑ ↑ none seen IIa Clear LDL ↑ ↑ normal +++ IIb LDL & VLDL III Turbid IDL ↑ ↑ ↑ IV VLDL + V Creamy top, turbid bottom VLDL & Chylomicrons

Laboratory Test Sample Collection Collect a fasting blood sample. Patient must have been fasting for at least 12hrs before the blood is taken to ensure that all chylomicrons from the last source of food have been cleared. 2. Place the separated plasma in a refrigerator and let stand overnight. Then check for the presence of a creamy layer, and note whether the plasma is clear or turbid. L

Observation of Plasma TURBID OR CLOUDY: increased VLDL CLEAR: elevated TC that must be caused by elevated LDL or HDL CREAMY TOP LAYER: increased chylomicrons

Laboratory Test Sample Collection cont… 3. Mix the sample, take aliquots, and measure the concentration of plasma total cholesterol and triglycerides. If an estimate of the risk of coronary artery disease is desired then the HDL cholesterol concentration is also measured. 4. Sometimes a lipoprotein electrophoretic pattern may aid in making finer distinctions

Determination of Total Cholesterol Enzymatic methods for the hydrolysis of cholesterol esters and oxidation of cholesterol are simpler, faster to perform and use less corrosive chemicals than the more tedious chemical analysis. The serum can be used directly, with little interference from other serum constituents.

Enzymatic Determination of Total Cholesterol cont… PRINCIPLE: Cholesteryl esters in the serum are hydrolysed by cholesterol ester hydrolase. All the cholesterol is then oxidised by cholesterol oxidase to the corresponding ketone, with a shift in the location of a double bond. The H₂O generated by the oxidation is decomposed by horseradish peroxidase in the presence of 4-aminoantipyrine and phenol to yield a quinoneimine dye The absorbance of the dye, measured at 500nm is proportional to the cholesterol concentration.

Determination of Plasma Triglycerides All laboratories today quantify triglycerides by measuring the glycerol moiety of the molecule after hydrolysis. They perform the analysis by utilising enzymes in every step from hydrolysis to liberate glycerol to the formation of the end products that are measured spectrophotometrically, fluorometrically, or colourmetrically dependind on the series of coupled enzymatic reactions and the end products. For example the disappearance of NADH is measured spectrophotometrically in one method and fluorometrically in another method.

Lipoprotein Electrophoresis The principle reason for requesting a lipoprotein electrophoresis is to ascertain the type of hyperlipoproteinemia in patients with hyperlipidemia. Lipoproteins carry an electric charge at pH 8.6 and can be separated by electrophoresis on ararose gel. Chylomicrons are uncharged and remain at the origin. After electrophoresis separation, the lipoproteins are stained with a fat stain; the support medium is destained and then dried. The lipoprotein bands and chylomicrons are visible because of the fat stain dissolved in them and abnormal bands can be seen upon visual inspection or quantified from a densitometric scan of the membrane

Other Tests Other tests are needed to rule out secondary causes of hyperlipoproteinemia such as: hypothyroidism, alcoholism and kidney disease. Therefore, when hyperlipoproteinemia is secondary to another disorder, treatment of the latter usually will correct the hyperlipoproteinemia.